Summary
Becton, Dickinson and Company (BDX) reported revenues of $7.37 billion for the fiscal year ended September 29, 2010, marking a 5.5% increase from the prior year, driven primarily by solid revenue growth in the Medical Segment. The company's strategic focus remains on increasing revenue growth through core product enhancement, investing in research and development for innovative products, expanding presence in emerging markets, improving operational efficiency, and driving shareholder returns. BD reported operating income of $1.7 billion, with a strong cash flow from operations totaling $1.7 billion, demonstrating financial health. The company also returned value to shareholders through share repurchases and dividends, while maintaining a solid investment-grade credit rating. Key areas of focus for BD include enabling safer drug delivery, improving clinical outcomes through advanced diagnostics, providing research tools, and enhancing disease management in areas like diabetes and infection control. The company is navigating a complex market with evolving regulatory environments and increased competition, but remains committed to its growth strategies. Despite some legal proceedings and the impact of healthcare reform legislation, BDX's financial position appears robust, supported by diversified revenue streams and a strong operational foundation.
Financial Highlights
54 data points| Revenue | $7.12B |
| Cost of Revenue | $3.43B |
| Gross Profit | $3.70B |
| R&D Expenses | $422.77M |
| SG&A Expenses | $1.69B |
| Operating Expenses | $5.54B |
| Operating Income | $1.58B |
| Interest Expense | $51.26M |
| Net Income | $1.32B |
| EPS (Basic) | $5.62 |
| EPS (Diluted) | $5.49 |
| Shares Outstanding (Basic) | 234.33M |
| Shares Outstanding (Diluted) | 240.14M |
Key Highlights
- 1Becton Dickinson (BDX) reported total revenues of $7.37 billion for fiscal year 2010, a 5.5% increase year-over-year, driven by the Medical segment.
- 2Operating income reached $1.7 billion, representing 22.7% of revenues, reflecting operational efficiency and growth.
- 3The company generated strong cash flow from operations of $1.7 billion, enabling robust financial flexibility.
- 4BDX actively returned capital to shareholders, repurchasing $750 million in common stock and paying $346 million in dividends during fiscal year 2010.
- 5The company made a strategic acquisition of HandyLab, Inc. for $275 million to enhance its molecular diagnostics capabilities.
- 6BDX is navigating significant risks including the impact of U.S. healthcare reform (likely excise tax on medical devices), foreign currency fluctuations, and competitive pressures.
- 7The company's diversified business segments (Medical, Diagnostics, Biosciences) and global presence provide a stable foundation despite market challenges.